Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210

• Published in: Cancer biology & medicine Vol. 16; no. 1; pp. 173 - 181
• Main Authors: Chen, Xuelian, Ma, Lanying, Wang, Xi, Mo, Hongnan, Wu, Dawei, Lan, Bo, Qu, Dong, Zhang, Hongtu, Huang, Jing, Xu, Binghe
• Format: Journal Article
• Language: English
• Published: China State Key Laboratory of Molecular Oncology and Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College-Medical Oncology, Beijing 100021, China%Department of Gastroenterology, Tumor Hospital Affiliated to Xinjiang Medical University, Tumor Hospital Affiliated to Xinjiang Medical University, Urumchi 830000, China%Department of Diagnostic Radiology, Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College-Medical Oncology, Beijing 100021, China%Department of Pathology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College-Medical Oncology, Beijing 100021, China 01.02.2019; Chinese Anti-Cancer Association; China Anti-Cancer Association
• Subjects: anti-tumor efficacy; Original; Reactive capillary hemangiomas; SHR-1210; skin toxicity; SHR-1210; Reactive capillary hemangiomas; anti-tumor efficacy; skin toxicity

SHR-1210 is a new and promising anti-PD-1 agent for solid tumors. During the phase I study of SHR-1210, we encountered a novel but prevalent immune-related dermatologic toxicity: reactive capillary hemangiomas (RCHs). Thus we tried to summarize the features of RCHs and estimate their relationship wi...